Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

Description: Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Eli Lilly and Company and Incyte Corporation are jointly developing baricitinib, an oral JAK1 and 2 inhibitor, under a worldwide license and collaboration agreement in which Lilly has the licensing rights. Baricitinib prevents intracellular signaling of IL-6 and IL-23, thereby reducing inflammation. Formerly known as LY3009104 to Lilly and as INCB28050 to Incyte, baricitinib is currently in Phase Ib clinical trials to study patients with active RA on background MTX. This trial is located in nine countries including the US and India. In addition to RA, baricitinib is in Phase Ib trials for the treatment of moderate to severe plaque psoriasis.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Baricitinib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Baricitinib for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Baricitinib performance
- Obtain sales forecast for Baricitinib from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Overview
Table 15: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
Figure 2: Rheumatoid Arthritis Biologic Drug Targets
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System
Figure 4: Severity of Rheumatoid Arthritis
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations-
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis |
| Web Address: | http://www.researchandmarkets.com/reports/2368643/ |
| Office Code: | SCD2ST6Z |

Product Formats
Please select the product formats and quantity you require:

| Quantity | Electronic (PDF) - Single User: | USD 3495 |
| Electronic (PDF) - Site License: | USD 6990 |
| Electronic (PDF) - Enterprisewide: | USD 10485 |

Contact Information
Please enter all the information below in BLOCK CAPITALS

| Title: | Mr | Mrs | Dr | Miss | Ms | Prof |
| First Name: | __________________________ | Last Name: | __________________________ |
| Email Address: * | __________________________ |
| Job Title: | __________________________ |
| Organisation: | __________________________ |
| Address: | __________________________ |
| City: | __________________________ |
| Postal / Zip Code: | __________________________ |
| Country: | __________________________ |
| Phone Number: | __________________________ |
| Fax Number: | __________________________ |

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World